No Data
No Data
Jinushi to Sell Prime Real Estate Holdings Across Japan
Jinushi (TYO:3252) will divest several real estate assets across Japan, according to a Tuesday filing on the Tokyo Stock Exchange. The properties, jointly owned with unit Jinushi Financial Advisors, a
Jinushi To Go Ex-Dividend On June 27th, 2024 With 42.5 JPY Dividend Per Share
June 26th (Japan Standard Time) - $Jinushi(3252.JP)$ is trading ex-dividend on June 27th, 2024.Shareholders of record on June 30th, 2024 will receive 42.5 JPY dividend per share. The ex-dividend date
Rising US bond prices, supported by the housing market.
Following signs of inflation deceleration in the United States, the US bond market rose sharply in June. It is expected that the housing market will also regain some vitality. The yield on 10-year bonds reached 4.212% on the 14th, nearly a 0.5 point decline from late May. It was the largest two-week decline this year. <2134> San Capital, <2337> Ichigo, <2970> Good Life C, <2975> Star Micah, <2976> Nichigrande. As requested, 不動産 is translated as a-reit etf and 住宅 as residence, 米国 as usa.
Stocks that moved the previous day part 1: Sellable online advertisements, Fujita Kanko, landowners, etc.
Stock name <code> 18 closing price on the 18th ⇒ Previous day comparison Trace OP<6696> 685 +71 announced the lifting of interim measures on credit regulations. FIG<4392> 340 +10 and Plus Zero<5132> announced a comprehensive partnership. Selling Net Advertising<9235> 2315 +212 announced the implementation of shareholder benefits for the first anniversary of listing. Recovery<9214> 1493 +78 announced a share buyback of up to 4.95% of the issued shares.
Daiwa Securities Starts Jinushi at Buy With 3,560 Yen Price Target
04:39 AM EDT, 06/18/2024 (MT Newswires) -- Daiwa Securities Starts Jinushi at Buy With 3,560 Yen Price Target
Fujita Kan, landlord, Terapro, etc.
<4502> Takeda Pharmaceutical Co., Ltd. fell sharply by 123 points to 4044 points. The clinical phase 3 trial results of "Soticlestat", a pediatric refractory epilepsy treatment drug under development, were announced the day before, leading to selling pressure. It seems that it was developed for "Dravet syndrome" which repeats convulsions and "Lennox-Gastaut syndrome" which has muscle weakness, but neither could achieve the main evaluation items. The performance impact associated with the current trial results, including impairment losses of intangible assets, will continue to be examined.
No Data